Splicing factor mutations in myelodysplasia
暂无分享,去创建一个
[1] T. Taniguchi,et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1 , 1994, Cell.
[2] C. Will,et al. The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.
[3] Joshua F. McMichael,et al. Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.
[4] A. Jankowska,et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. , 2012, Blood.
[5] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[6] Xiang-Dong Fu,et al. Splicing Regulator SC35 Is Essential for Genomic Stability and Cell Proliferation during Mammalian Organogenesis , 2007, Molecular and Cellular Biology.
[7] T. Komori,et al. Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1. , 2005, Genes & development.
[8] S. Ogawa,et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). , 2012, Blood.
[9] Yong-mei Zhu,et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia , 2011, Nature Genetics.
[10] S. Ogawa,et al. Novel splicing-factor mutations in juvenile myelomonocytic leukemia , 2012, Leukemia.
[11] T. Owa,et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide , 2007, Nature Chemical Biology.
[12] O. Abdel-Wahab,et al. The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.
[13] R. Levine,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[14] Franco Locatelli,et al. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. , 2012, Blood.
[15] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[16] A. Hagemeijer,et al. Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.
[17] M. Carroll,et al. A common genetic mechanism in malignant bone marrow diseases. , 2009, The New England journal of medicine.
[18] J. Licht,et al. DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.
[19] B. Ko,et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. , 2012, Blood.
[20] L. Chin,et al. Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.
[21] P. Potter,et al. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. , 2013, Drug discovery today.
[22] A. Jankowska,et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts , 2012, Leukemia.
[23] T. Haferlach,et al. Molecular genetics in acute myeloid leukemia , 2010, Current opinion in oncology.
[24] M. Minden,et al. Myelodysplastic syndromes: the complexity of stem-cell diseases , 2007, Nature Reviews Cancer.
[25] L. Larocca,et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome , 2012, British journal of haematology.
[26] A. Sivachenko,et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.
[27] Michael Heuser,et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.
[28] M. Heuser,et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications , 2012, Leukemia.
[29] J. Manley,et al. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches , 2009, Nature Reviews Molecular Cell Biology.
[30] G. Garcia-Manero,et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. , 2012, Blood.
[31] Benjamin L Ebert,et al. Unraveling the molecular pathophysiology of myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] L. Pasqualucci,et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.
[33] Xiang-Dong Fu,et al. A protein related to splicing factor U2AF35 that interacts with U2AF65 and SR proteins in splicing of pre-mRNA , 1997, Nature.
[34] Peter J Campbell,et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.
[35] T. Haferlach,et al. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms , 2013, Haematologica.
[36] Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia , 2011 .
[37] A. Jankowska,et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.
[38] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.
[39] D. Neuberg,et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Gönen,et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. , 2012, Blood.
[41] Li Ding,et al. RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES , 2011, Nature Genetics.
[42] A. Tefferi,et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients , 2012, Leukemia.
[43] R. Gale,et al. Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts. , 2012, Leukemia research.
[44] Claude Preudhomme,et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. , 2012, Blood.
[45] E. Giné,et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.
[46] O. Bernard,et al. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies , 2012, Leukemia.
[47] M. Hagiwara,et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA , 2007, Nature Chemical Biology.